局部使用阿昔洛韦及其相关制剂治疗复发性唇疱疹的系统评价

Topical acyclovir and related agents for treatment of recurrent herpes labialis: a systematic review

目的:评价局部使用阿昔洛韦及其制剂治疗复发性唇疱疹的疗效和安全性。方法:计算机检索Pub Med、Cochrane Library、Clinical Trials、中国学术文献总库(CNKI)及万方数据库。搜集2015年9月之前公开发表的局部应用阿昔洛韦及其相关制剂治疗复发性唇疱疹的随机对照实验,并筛检纳入文献的参考文献。由2名研究者参与文献筛选、资料提取和质量评价。对符合纳入标准的随机对照实验进行描述和Meta分析。结果:共纳入5篇文献,总计3013名患者。Meta分析结果显示:局部应用阿昔洛韦或其相关制剂实验组比空白对照组、传统5%阿昔洛韦软膏比空白组、阿昔洛韦相关制剂比空白组,均可显著缩短病损愈合时间(MD=-0.64,95%CI:-0.87^-0.41;MD=-0.55[-0.84;-0.26];MD=-0.79[-1.17;-0.14]);而传统的5%阿昔洛韦软膏与阿昔洛韦相关制剂在促进病损愈合方面无明显差异(MD=-1.12[-3.64;1.39])。结论:局部使用阿昔洛韦或其相关制剂均可缩短复发性唇疱疹病损愈合时间,且无明显差异。

Objective：To systematically assess the efficacy and safety of topical acyclovir and related agents on recurrent herpes labialis treatment. Method：Randomized clinical trials（RCT） comparing topical acyclovir or related agents with placebo for treatment of recurrent herpes labialis were retrieved from Pub Med, Cochrane Library, Clinical Trials, CNKI and Wangfan Database until Sept. 30, 2015. And References of the included studies were also searched. Two reviewers selected literature, extracted data and did quality evaluation. The dates met the eligible criteria were abstracted and analyzed.Result：Five randomized controlled trials, including 3013 participants, were involving. Meta-analysis showed a significant shorten on healing time in topical acyclovir or related agents group compared with placebo group（MD=-0.64, 95 %CI：-0.87^-0.41; MD=-0.55[-0.84;-0.26]; MD=-0.79[-1.17;-0.14]）. Conclusion：Topical acyclovir or related agents can shorten the healing time of recurrent herpes labialis lesion, without significant differency.